Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
Scientific presentation

Precision over bulk sequencing


Koichi Takahashi, MD
Dennis Eastbur, PhD
Jerry Radich, MD

Description

Fifty percent (50%) of patients with acute myeloid leukemia (AML) relapse and develop a more virulent form of the disease. To better understand AML and the cancer hematological ecosystem, it is necessary to discern clonal architecture and the dynamics of competing clones, which provide valuable insight into therapy response. It takes three or more mutations for leukemia to form. This can occur in the same cell or within the tumor microenvironment, but how do you discern this information with bulk sequencing? Dr. Jerry Radich, of Stanford Medical Center, and Dr. Koichi Takahashi, of MD Anderson, share their research on how they identified mutations within rare subclones using single-cell analysis for precision over bulk sequencing.



VIEW


Scientific presentation
Single cell Genotypic and Immunotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia
Ross Levine, MD
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Bioinformatics approach to demultiplexing scMRD
Troy Robinson, MSKCC
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Opportunities for Single-cell Multi-omics in the Clinic: MRD and Beyond
Ross Levine
Marina Konopleva
Saar Gill
Wenbin Xiao
Mikhail Roshal
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Single-cell Multi-omics and the Horizon of Clinical Utility
Aaron Llanso
(2022)
REQUEST QUOTE